wilson's disease - SPORTS
Seeking Alpha: Monopar a new outperform at Oppenheimer on Wilson disease candidate Oppenheimer has initiated Monopar Therapeutics at outperform citing the potential of a candidate for the genetic disorder Wilson disease it acquired from AstraZeneca (AZN). The firm set a $77 price ... EurekAlert!: A multimodal neuroimaging and hepatic imaging analysis for hepatic-type and neurological-type Wilson’s disease This multimodal MRI study shows that hepatic iron deposition, brain iron accumulation, and selective brain atrophy differ between hepatic-type (HWD) and neurological-type Wilson’s disease (NWD).
Context Explanation
A multimodal neuroimaging and hepatic imaging analysis for hepatic-type and neurological-type Wilson’s disease Nasdaq: Eton Pharmaceuticals Launches Galzin® With $0 Co-Pay Program to Enhance Access for Wilson Disease Patients Eton Pharmaceuticals has launched Galzin® (zinc acetate) capsules, the only FDA-approved zinc therapy for Wilson disease patients who have previously been treated with a chelating agent. To enhance ... Eton Pharmaceuticals Launches Galzin® With $0 Co-Pay Program to Enhance Access for Wilson Disease Patients Research seems to be gaining ground in Wilson disease, a rare inherited condition that causes copper levels to accumulate in the liver, brain and eyes. Most people are diagnosed as children or around ...
Image Collection
Insight Material
Nasdaq: Monopar Therapeutics Presents Long-Term Efficacy and Safety Data for ALXN1840 in Wilson Disease at EASL International Liver Congress 2025 Monopar Therapeutics Inc. presented new data on its drug candidate ALXN1840 (tiomolybdate choline) for Wilson disease at the European Association for the Study of the Liver International Liver ... Monopar Therapeutics Presents Long-Term Efficacy and Safety Data for ALXN1840 in Wilson Disease at EASL International Liver Congress 2025 Seeking Alpha: Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate Edex Live on MSN: The silent progression of Wilson’s disease and delayed diagnosis Wilson’s disease is not something most people would think about, until it suddenly enters a conversation, often through a story that feels too close to home. It is a rare genetic condition, quiet in ...